Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 31, 2025

Trump 2.0, stocks soar again, gold hits records, AI boom rolls on — Yahoo Finance's 2025 year in review

View original at finance.yahoo.com
Trump 2.0, stocks soar again, gold hits records, AI boom rolls on — Yahoo Finance's 2025 year in review When the closing bell rings on Wall Street Wednesday afternoon, the S&P 500 (^GSPC) will clinch its third straight year of double-digit gains and end the year near a record high…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Lisa Cook fired for alleged mortgage fraud related to buying two properties

    80% confidence

  • AI-related investment will be notably larger than $71 billion planned for 2025

    80% confidence

  • Economic outlook and labor market changes may warrant shift in Fed's interest rate stance

    80% confidence

  • Called market rally the 'biggest day in financial history'

    80% confidence

  • DeepSeek AI model can rival OpenAI models for a fraction of the cost

    80% confidence

  • This is a critical time for ChatGPT after Gemini 3 release

    80% confidence

  • Criticized One Big Beautiful Bill as a 'disgusting abomination'

    80% confidence

  • Tesla's autonomous future will focus far less on selling cars

    80% confidence

  • Authorized 90 day pause and substantially lowered reciprocal tariff to 10%, while raising China tariffs to 125%

    80% confidence

  • Recommended to Berkshire board that Greg Abel be designated CEO with start date of Jan 1, 2026

    80% confidence

  • Stock and bond market was 'yippy' and people were jumping a bit out of line

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com